Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast

Pharmacogenetics and Genomics

Volumn 17, Issue 3, 2007, Pages 189-196

  Klotsman, Michael ^a   York, Timothy P ^b   Pillai, Sreekumar G ^a   Vargas Irwin, Cristina ^b   Sharma, Sanjay S ^a   Van Den Oord, Edwin J C G ^b   Anderson, Wayne H ^a  

^a GLAXOSMITHKLINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Asthma; Leukotriene; Montelukast; Pharmacogenetics

Indexed keywords

ADRB2 PROTEIN; ALOX5 PROTEIN; ALOX5AP PROTEIN; ARACHIDONATE 5 LIPOXYGENASE; CYP2C9 PROTEIN; CYP3A4 PROTEIN; CYSLTR1 PROTEIN; CYSLTR2 PROTEIN; FLUTICASONE PROPIONATE PLUS SALMETEROL; GENE PRODUCT; LTC4S PROTEIN; MONTELUKAST; NR3C1 PROTEIN; PEPTIDOLEUKOTRIENE; PLA2G4A PROTEIN; SALBUTAMOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHMA; BIOSYNTHESIS; CONTROLLED STUDY; DATA ANALYSIS; ENZYME SYNTHESIS; EXPIRATORY FLOW; FEMALE; FORCED EXPIRATORY VOLUME; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SECRETION; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT RESPONSE; WILD TYPE;

ACETATES; ADOLESCENT; ADULT; ARACHIDONATE 5-LIPOXYGENASE; ASTHMA; DOUBLE-BLIND METHOD; FEMALE; HAPLOTYPES; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PHARMACOGENETICS; PLACEBOS; QUINOLINES; RECEPTORS, LEUKOTRIENE; SIGNAL TRANSDUCTION;

EID: 34247561179     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3280120043     Document Type: Article

References (51)

1. Luster AD, Tager AM. T-cell trafficing in asthma: lipid mediators grease the way. Nat Rev Immunol 2004; 4:711-724.
2. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983; 220:568-575.
3. Diamant Z, Hiltermann J, van Rensen E, Callenbach PM, Veselic-Charvat M, van der Veen H, et al. The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma. Am J Respir Crit Care Med 1997; 155:1247-1253.
4. Drazen Jeffrey M. Leukotrienes as mediators of airway obstruction. Am J Respir Crit Care Med 1998; 158:193S-200S.
5. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340:197-206.
6. Lynch KR, O'Neill GP, Liu Q, Dong-Soon LM, Sawyer N, Metters KM, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999; 399:789-793.
7. Back M. Functional characteristics of cysteinyl-leukotriene receptor subtypes. Life Sci 2002; 71:611-622.
8. Pillai SG, Cousens DJ, Barnes AA, Buckley PT, Chiano MN, Hosking LK et al. A coding polymorphism in the CYSLT2 receptor with reduced affinity to LTD4 is associated with asthma. Pharmacogenetics 2004; 14:627-633.
9. Thompson MD, van's Gravesande KS, Galczenski H, Burnham WM, Siminovitch KA, Zamel N, et al. A cysteinyl leukotriene 2 receptor variant is associated with atopy in the population of Tristan da Cunha [erratum appears in Pharmacogenetics 2003; 13:704]. Pharmacogenetics 2003; 13:641-649.
10. Drazen JM, Yandava CN, Dube L, Szczerback N, Hippensteel R, Pillari A, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22:168-170.
11. Sampson AP, Siddiqui S, Buchanan D, Howarth PH, Holgate ST, Holloway JW, Sayers I, et al. Variant LTC4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000; 55:28S-31S.
12. Busse W, Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest 2005; 127:1312-1326.
13. Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Pineiro A, Wei LX, et al. Oral montelukast, inhaled Beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Ann Intern Med 1999; 130:487-495.
14. Barnes PJ. Anti-leukotrienes: here to stay? Curr Opin Pharmacol 2003; 3:257-263.
15. Barnes PJ. New drugs for asthma. Nat Rev Drug Discov 2004; 3:831-844.
16. Shore SA, Drazen JM. beta-Agonists and asthma: too much of a good thing? J Clin Invest 2003; 112:495-497.
17. Whitsett JA, Bachurski CJ, Barnes KC, Bunn PA, Case LM, Cook DN, et al. Functional genomics of lung disease. Am J Respir Cell Mol Biol 2004; 31:S1-S81.
18. Pearlman DS, White MV, Lieberman AK, Pepsin PJ, Kalberg C, Emmett A, et al. Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. Ann Allergy, Asthma Immunol 2002; 88:227-235.
19. Calhoun WJ, Nelson HS, Nathan RA, Pepsin PJ, Kalberg C, Emmett A, et al. Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone. [see comment]. Am J Respir Crit Care Med 2001; 164:759-763.
20. Society AT. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis 1987; 136:225-244.
21. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 2000; 97:10483.
22. Dekker FW, Schrier AC, Sterk PJ, Dijkman JH, et al. Validity of peak expiratory flow measurement in assessing reversibility of airflow obstruction. Thorax 1992; 47:162-166.
23. GINA. Global strategy for asthma management and prevention. Global Initiative for Asthma, 2002; NIH Pub. No. 02-3659.
24. Storey JD. A direct approach to false discovery rates. J R Statis Soc: Series B (Statis Methodol) 2002; 64:479-498.
25. Storey JD. The postive false discovery rate: a bayesian interpretation and the q-value. Ann Statis 2003; 31:2013-2035.
26. Hsueh H, Chen JJ, Kodell RL. Comparison of methods for estimating the number of true null hypotheses in multiplicity testing. J Biopharm Stat 2003; 13:675-689.
27. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statis Soc: Series B (Statis Methodol) 1995; 57:289-300.
28. Brown BW, Russell K. Methods of correcting for multiple testing: operating characteristics. Statis Med 1997; 16:2511-2528.
29. Zeiger RS, Bird SR, Kaplan MS, Schatz M, Pearlman DS, Orav EJ, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 2006; 117:45-52.
30. Korn EL, Troendle JF, McShane LM, Simon R, et al. Controlling the number of false discoveries: application to high-dimensional genomic data. J Stat Planning Inference 2004; 124:379-398.
31. Tsai CA, Hsueh HM, Chen JJ. Estimation of false discovery rates in multiple testing: application to gene microarray data. Biometrics 2003; 59: 1071-1081.
32. van den Oord EJ, Sullivan PF. A framework for controlling false discovery rates and minimizing the amount of genotyping in the search for disease mutations. Hum Hered 2003; 56:188-199.
33. Barrett JC, Fry B, Maller J, Daly MJ et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265.
34. Stram DO. Tag SNP selection for association studies. Genet Epidemiol 2004; 27:365-374.
35. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science 2002; 296:2225-2229.
36. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003; 25:115-121.
37. Lima JJ, Zhang S, Grant A, Shao L, Tantisira KG, Allayee H, et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med 2006; 173:379-385.
38. Fowler S, Hall I, Wilson A, Wheatley A, Lipworth B, et al. 5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists. Eur J Clin Pharmacol 2002; 58:187-190.
39. Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Dong-Soon IM, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000; 275:30531-30536.
40. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Brit Med Bull 2000; 56:1054.
41. Fukai H, Ogasawara Y, Migita O, Koga M, Ichikawa K, Shibasaki M, et al. Association between a polymorphism in cysteinyl leukotriene receptor 2 on chromosome 13q14 and atopic asthma. Pharmacogenetics 2004; 14:683-690.
42. Park JS, Chang HS, Park C, Lee J-H, Lee YM, Choi JH, et al. Association analysis of cysteinyl-leukotriene receptor 2 (CYSLTR2) polymorphisms with aspirin intolerance in asthmatics. Pharmacogenet Genomics 2005; 15:483-492.
43. Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma [see comment]. J Allergy Clin Immunol 2005; 115:233-242.
44. McGraw DW, Almoosa KF, Paul RJ, Kobilka BK, Liggett SB, et al. Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox. J Clin Invest 2003; 112:619-626.
45. Callaerts-Vegh Z, Evans KLJ, Dudekula N, Cuba D, Knoll BJ, Callaerts PFK, et al. Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci U S A 2004; 101:4948-4953.
46. Weiss ST, Litonjua AA, Lange C, Lazarus R, Liggett SB, Bleecker ER, Tantisira KG, et al. Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics J 2006; 6:311-326.
47. Ilowite J,Webb R, Friedman B, Kerwin E, Bird SR, Hustad CM, Edelman JM, et al. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Ann Allergy, Asthma, Immunol 2004; 92:641-648.
48. Zeiger RS, Bird SR, Kaplan MS, Schatz M, Pearlman DS, Orav EJ, et al. Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial. Am J Med 2005; 118:649-657.
49. Ram FS, Cates CJ, Ducharme FM. Long-acting beta2-agonists versus antileukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database of Syst Rev 2005:CD003137.
50. Jayaram L, Pizzichini E, Lemiere C, Man SF, Cartier A, Hargreave FE, Pizzichini MM, et al. Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast. Thorax 2005; 60:100-105.
51. O'Connor RD, Stanford R, Crim C, Yancey SW, Edwards L, Rickard KA, Dorinsky P, et al. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs. Ann Allergy, Asthma, Immunol 2004; 93:581-588.